Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Industry

15 Mar 2022

Global Wellness Institute Announces New Psychedelics Initiative

The Initiative will support collaboration and coalition building, and ethics and best practices, in the psychedelic community....

By Microdose

Industry

10 Mar 2022

Small Pharma Expands Clinical Trial Pipeline

Lead DMT-assisted therapy candidate SPL026’s clinical development program strengthened with the addition of two clinical trials planned for 2022...

By Microdose

Events

8 Mar 2022

PsyCap Recap: PurMinds NeuroPharma

​PurMinds executive team joined us at the last Psychedelic Capital event to present their work and discuss what makes their plan different....

By Microdose

Breaking News, Industry

1 Mar 2022

Calgary-based Med Plant Science Ltd. granted license to research and develop psychedelics in St Vincent and the Grenadines

Calgary-based biotech company, Med Plant Science Ltd, has been awarded a license for medicinal plants containing psychedelic compounds by the St....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

17 Feb 2022

Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress

Clinical trial aim is to include the identification and characterization of the Cancer Related Distress symptoms most responsive to psychedelic-associated therapy...

By Microdose

Events

15 Feb 2022

PsyCap Recap Jan 2022: Entheo Digital

Entheo Digital is working to position itself as a leading innovator in this space....

By Microdose

Events

15 Feb 2022

PsyCap Recap: HAVN Life Sciences

HAVN Life CEO Tim Moore and Spore Life CEO Michael Zavet joined Microdose’s Patrick Moher at the recent Psychedelic Capital event...

By Microdose

Industry

14 Feb 2022

Microdose Launches Network of Local Events: Microdose X

These local events will feature talks from experts, artists’ presentations, and opportunities to connect with other psychedelic community members....

By Microdose

Psychedelic Titans

11 Feb 2022

Psychedelic Titans with Edward Pearson of KetaMD.com

Psychedelic Titan Edward Pearson is Medical Director of KetaMD....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.